To overcome this issue, the authors utilized the JAK/STAT inhibitor, ruxolitinib, in combination with VSV-IFNβ to see if inhibition of the signaling could enhance VSV-IFNβ therapy for lung cancer [204]. Here, IFNB1 is linked to lung cancer.